Published Date : Aug 21, 2017
Albany, New York, August 21, 2017: MarketResearchReports.biz has recently added a detailed market research report covering the present state of clinical and commercial landscape of the global liver cancer market. The report is titled “Frontier Pharma: Liver Cancer - Identifying and Commercializing First-in-Class Innovation.” The report presents a comprehensive account of the pathogenesis, prognosis, diagnosis, and the treatment options available for liver cancer across the globe.
The report includes vast data for the readers to gain a thorough understanding of the composition of the global liver cancer market, highlighting the most urgent unmet needs and the dominant molecule types either in the pipeline or in the market. The comprehensive data allows a detailed understanding of gaps and thus opportunities that can be exploited in the market.
According to 2012 data, although liver cancer is the sixth common type of cancer, its poor diagnosis makes it the world’s second leading factor causing cancer-related deaths. There is a very limited range of therapies and treatment options to cure liver cancer; chemotherapies remained the treatment of choice for several years and targeted therapies have only recently started to emerge in the global market.
For Sample Copy, click here: https://www.marketresearchreports.biz/sample/sample/1287796
The report segments the global liver cancer market in terms of the need of treatment. Patients diagnosed in the early-stage of the disease have the option of surgical resection and other curative therapies, thus having a positive outlook. However, for the patients diagnosed in the later stages of the disease, representing a massive share of the global patient population, do not have the option of surgery and have a very poor prognosis in spite of several targeted therapies such as Stivarga (regorafenib) and Nexavar (sorafenib).
The market has a relatively limited product portfolio, containing only 86 products. However, the global pipeline of liver cancer drugs is diverse, large, and includes highly innovative products. According to the report, the pipeline includes 423 products in the stage of active development, with diversity in terms of both action mechanisms and molecule type. Of these, 122 products are first-in-class and target 109 distinct first-in-class molecules. These products span a vast range of molecular target varieties, including targeted cytotoxic agents, cancer immunotherapies, kinase inhibitors, and receptor tyrosine kinases, far exceeding the number and scope of products available in the chemotherapy-dominated market.
The report allows easy differentiation of drugs in the pipeline in terms of molecular target, molecule type, and state of development. The pipeline shows that the industry is focusing more on innovative approaches related to the treatment of subtypes of liver cancer, including cholangiocarcinoma and hepatocellular carcinoma. The report’s data could help readers assess the potential of treatment of the first-in-class targets. With the help of a proprietary molecular target matrix, the report presents an reports of the key first-in-class products in the pipeline, ranking them according to therapeutic potential.
To order report Call Toll Free: 866-997-4948 or send an email on email@example.com